Alerts will be sent to your verified email
Verify EmailRPGLIFE
RPG Life Sciences
|
Hikal
|
Gufic Biosciences
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
-11.18 % | n/a | n/a |
R&D as a % of Total Sales
|
1.11 % | 4.01 % | 0.83 % |
Financials
|
|||
5 yr Average ROE
|
23.71 % | 10.48 % | 25.05 % |
5yr average Equity Multiplier
|
1.34 | 2.17 | 2.22 |
5yr Average Asset Turnover Ratio
|
1.18 | 0.81 | 1.05 |
5yr Avg Net Profit Margin
|
15.65 % | 5.87 % | 10.9 % |
Price to Book
|
7.33 | 3.1 | 6.41 |
P/E
|
21.27 | 43.07 | 55.31 |
5yr Avg Cash Conversion Cycle
|
-53.67 Days | 33.87 Days | 26.94 Days |
Inventory Days
|
61.98 Days | 64.21 Days | 66.86 Days |
Days Receivable
|
35.4 Days | 101.46 Days | 128.09 Days |
Days Payable
|
143.49 Days | 96.57 Days | 163.91 Days |
5yr Average Interest Coverage Ratio
|
30.59 | 4.8 | 13.1 |
5yr Avg ROCE
|
28.37 % | 13.73 % | 27.25 % |
5yr Avg Operating Profit Margin
|
20.94 % | 16.42 % | 18.45 % |
5 yr average Debt to Equity
|
0.0 | 0.68 | 0.51 |
5yr CAGR Net Profit
|
35.58 % | -3.79 % | 14.26 % |
5yr Average Return on Assets
|
17.85 % | 4.82 % | 11.52 % |
Shareholdings
|
|||
Promoter Holding
|
72.95 % | 68.85 % | 72.52 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.54 % | 0.08 % | -2.48 % |
Change in Mutual Fund Holding (3 Yrs)
|
3.38 % | 2.2 % | 2.35 % |
RPG Life Sciences
|
Hikal
|
Gufic Biosciences
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|